Association of CT60 polymorphism of the CTLA4 gene with Graves' disease in Taiwanese children

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 7, 2008, Pages 665-671

  Tsai, Suei Tsau ^a   Huang, Chi Yu ^b,c   Lo, Fu Sung ^d   Chang, Ya Ting ^a   Tanizawa, Takakuni ^e   Chen, Chi Kai ^b   Wang, Zen Chong ^b   Liu, Hsin Fu ^b   Chu, Chen Chung ^b   Lin, Marie ^b   Lin, Chao Hsu ^b   Li, Hsin Jung ^f   Lee, Yann Jinn ^b,g  

^a TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

^f ST MARTIN DE PORRES HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Child; CT60; CTLA4 gene; Graves' disease; Taiwan

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

EID: 51349123893     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.7.665     Document Type: Article

References (69)

1. Jaksic J, Dumic M, Filipovic B, Ille J, Cvijetic M, Gjuric G. Thyroid diseases in a school population with thyromegaly. Arch Dis Child 1994; 70: 103-106.
2. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995; 43: 55-68.
3. Meskin LH, Entwistle B. Current and future projections of dental school patient availability. J Dent Educ 1985; 4: 565-569.
4. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86: 930-934.
5. Todd JA. The emperor's new genes: 1993 RD Lawrence Lecture. Diabet Med 1994; 11: 6-16.
6. Chert QY, Huang W, She JX, Baxter F, Volpe R, Maclaren NK. HLA-DRB1*08, DRB1*03/DRB3*010l, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999; 84: 3182-3186.
7. Boehm BO, Kuhnl P, Manfras BJ, Chen M, Lee JC, Holzberger G, Seidl S, Schifferdecker E, Schumm-Draeger PM, Usadel KH. HLA-DRB3 gene alleles in Caucasian patients with Graves' disease. Clin Investig 1992; 70: 956-960.
8. Zamani M, Spaepen M, Bex M, Bouillon R, Cassiman JJ. Primary role of the HLA class II DRBI*0301 allele in Graves disease. Am J Med Genet 2000; 95: 432-437.
9. Lo FS, Lee YJ, Huang CY, Lin CH, Chang SC, Dang CW, Liu HF. Polymorphism in the transmembrane region of the major histocompatibility complex class I chain-related gene A: association of five GCT repetitions with Graves' disease in children. Thyroid 2003; 13: 839-842.
10. Davies TF, Larsen PR. Thyrotoxicosis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology, 10th Ed. St. Louis, MO: WB Saunders Co., 2003, 374-421.
11. Lavard L, Ranlov I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study. Eur J Endocrinol 1994; 130: 565-568.
12. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000; 85: 1984-1988.
13. Martin A, Goldsmith NK, Friedman EW, Schwartz AE, Davies TF, Roman SH. Intrathyroidal accumulation of T cell phenotypes in autoimmune thyroid disease. Autoimmunity 1990; 6: 269-281.
14. Paschke R, Bruckner N, Schmeidl R, Pfiester P, Usadel KH. Predominant intraepithelial localization of primed T cells and immunoglobulin-producing lymphocytes in Graves' disease. Acta Endocrinol 1991; 124: 630-636.
15. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 1995; 16: 306-310.
16. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray GS. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 1995; 92: 811-815.
17. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-988.
18. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howler S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, lonescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511.
19. Weng YC, Wu MJ, Lin WS. CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population. Ann Clin Lab Sci 2005; 35: 259-264.
20. Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, Xie Y, Mao Y. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and metaanalysis. Hum Immunol 2006; 67: 618-626.
21. Cho HJ, Chung JH, Kim IS, Kim HJ, Cho SH, Ki CS, Kim JW. Lack of a genetic association between the CTLA-4 gene and Graves' disease in Koreans. Thyroid 2006; 16: 237-241.
22. Pearce SH, Merriman TR. Genetic progress towards the molecular basis of autoimmunity. Trends Mol Med 2006; 12: 90-98.
23. Barlow AB, Wheatcroft N, Watson P, Weetman AP. Association of HLA-DQAl*0501 with Graves' disease in English Caucasian men and women. Clin Endocrinol 1996; 44: 73-77.
24. Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y. Association of a CTLA-4 3′ untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population. Autoimmunity 2005; 38: 151-153.
25. Ohashi J, Yamamoto S, Tsuchiya N, Hatta Y, Komata T, Matsushita M, Tokunaga K. Comparison of statistical power between 2 * 2 allele frequency and allele positivity tables in case-control studies of complex disease genes. Ann Hum Genet 2001; 65: 197-206.
26. Buffone GJ, Darlington GJ. Isolation of DNA from biological specimens without extraction with phenol. Clin Chem 1985; 31: 164-165.
27. Lee HH, Chao HT, Ng HT, Choo KB. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996; 33: 371-375.
28. Orozco G, Torres B, Nunez-Roldan A, Gonzalez-Escribano MF, Martin J. Cytotoxic T-lymphocyte antigen-4-CT60 polymorphism in rheumatoid arthritis. Tissue Antigens 2004; 64: 667-670.
29. Hedrick PW. Measurement of genetic variation. In: Hedrick PW, ed. Genetics of Populations, 2nd Ed. Sudbury, MA: Jones and Bartlett Publishers, 2000; 47-87.
30. Lee YJ, Chen MR, Chang WC, Lo FS, Huang FY. A freely available statistical program for testing associations (freely available on request to yannleeμs2. mmh. org.tw). MD Comput 1998; 15: 327-330.
31. Farid NR, Stone E, Johnson G. Graves' disease and HLA: clinical and epidemiological associations. Clin Endocrinol 1980; 13: 535-544.
32. Lavard L, Madsen HO, Perrild H, Jacobsen BB, Svejgaard A. HLA class II associations in juvenile Graves' disease: indication of a strong protective role of the DRB1*0701,DQA1*0201 haplotype. Tissue Antigens 1997; 50: 639-641.
33. Inoue D, Sato K, Enomoto T, Sugawa H, Maeda M, Inoko H, Tsuji K, Mori T, Imura H. Correlation of HLA types and clinical findings in Japanese patients with hyperthyroid Graves' disease: Evidence indicating the existence of four subpopulations. Clin Endocrinol (Oxf) 1992; 36: 75-82.
34. Onuma H, Ota M, Sugenoya A, Inoko H. Association of HLA-DPB1*0501 with early-onset Graves' disease in Japanese. Hum Immunol 1994; 39: 195-201.
35. Yeo PP, Chan SH, Thai AC, Ng WY, Lui KF, Wee GB, Tan SH, Lee BW, Wong HB, Cheah JS. HLA Bw46 and DR9 associations in Graves' disease of Chinese patients are age- and sex-related. Tissue Antigens 1989; 34: 179-184.
36. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol 2005; 62: 679-682.
37. Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J. An Mse I RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996; 225: 817-818.
38. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991; 147: 1037-1044.
39. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988; 18: 1901-1905.
40. Polymeropoulos MH, Xiao H, Rath DS, Merril CR Dinucleotide repeat polymorphism at the human CTLA4 gene. Nucleic Acids Res 1991; 19: 4018.
41. Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC, Holder RL, Barnett AH, Franklyn JA, Gough SC. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999; 84: 2398-2401.
42. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P, Todd JA. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996; 5: 1075-1080.
43. Ban Y, Concepcion ES, Villanueva R, Greenberg DA, Davies TF, Tomer Y. Analysis of immune regulatory genes in familial and sporadic Graves' disease. J Clin Endocrinol Metab 2004; 89: 4562-4568.
44. Torres B, Aguilar F, Franco E, Sanchez E, Sanchez-Roman J, Jimenez Alonso J, Nunez-Roldan A, Martin J, Gonzalez-Escribano MF. Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2211-2215.
45. Furugaki K, Shirasawa S, Ishikawa N, Ito K, Ito K, Kubota S, Kuma K, Tamai H, Akamizu T, Hiratani H, Tanaka M, Sasazuki T. Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese. J Hum Genet 2004; 49: 166-168.
46. Wang PW, Liu RT, Juo SH, Wang ST, Hu YH, Hsieh CJ, Chen MH, Chen IY, Wu CL. Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. J Clin Endocrinol Metab 2004; 89: 169-173.
47. Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M, Nauman J. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur J Endocrinol 2003; 148: 13-18.
48. Maalej A, Bougacha N, Rebai A, Bellassouad M, Ayadi-Makni F, Abid M, Jouida J, Makni H, Ayadi H. Lack of linkage and association between autoimmune thyroid diseases and the CTLA-4 gene in a large Tunisian family. Hum Immunol 2001; 62: 1245-1250.
49. Bednarczuk T, Gopinath B, Ploski R, Wall JR. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol 2007; 67: 3-19.
50. Petrone A, Giorgi G, Galgani A, Alemanno I, Corsello SM, Signore A, Di Mario U, Nistico L, Cascino I, Buzzetti R. CT60 single nucleotide polymorphisms of the cytotoxic T-lymphocyte-associated antigen-4 gene region is associated with Graves' disease in an Italian population. Thyroid 2005; 15: 232-238.
51. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
52. Risch N. Searching for genes in complex diseases: lessons from systemic lupus erythematosus. J Clin Invest 2000; 105: 1503-1506.
53. Matron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Larrad MT, Teng WP, Park Y, Zhang ZX, Goldstein DR, Tao YW, Beaurain G, Bach JF, Huang HS, Luo DF, Zeidler A, Rotter JI, Yang MC, Modilevsky T, Maclaren NK, She JX. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997; 6: 1275-1282.
54. Schaid DJ. Transmission disequilibrium, family controls, and great expectations. Am J Hum Genet 1998; 63: 935-941.
55. Pericak-Vance MA. Basic concepts in linkage analysis. In: Haines JL, Pericak-Vance MA, eds. Approaches to Gene Mapping in Complex Human Diseases. New York: Wiley-Liss, 1998; 77-92.
56. Haines JL. Affected relative pair analysis. In: Haines JL, Pericak-Vance MA, eds. Approaches to Gene Mapping in Complex Human Diseases. New York: Wiley-Liss, 1998; 305-321.
57. LaFranchi S. Hyperthyroidism. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics, 17th Ed. Philadelphia, PA: Elsevier Science, 2004; 1884-1888.
58. DeGroot LJ, Quintans J. The causes of autoimmune thyroid disease. Endocr Rev 1989; 10: 537-562.
59. Dayan CM, Londei M, Corcoran AE, Grubeck-Loebenstein B, James RF, Rapoport B, Feldmann M. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci USA 1991; 88: 7415-7419.
60. Iitaka M, Aguayo JF, Iwatani Y, Row VV, Volpe R. Studies of the effect of suppressor T lymphocytes on the induction of antithyroid microsomal antibody-secreting cells in autoimmune thyroid disease. J Clin Endocrinol Metab 1988; 66: 708-714.
61. Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000; 164: 4465-4470.
62. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune disease. N Engl J Med 1996; 335: 1369-1377.
63. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999; 29: 3596-3602.
64. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164: 5015-5018.
65. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000; 20: 144-153.
66. Huang D, Giscombe R, Zhou Y, Pirskanen R, Lefvert AK. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol 2000; 105: 69-77.
67. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000, 165: 6606-6611.
68. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002; 54: 1-8.
69. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J Clin Endocrinol Metab 2001; 86: 1687-1693.